Compounded Low Dose Naltrexone (LDN) topical cream prepared per prescriber direction for individualized care plans. Prescription required.
Low Dose Naltrexone (LDN) Topical Cream – According to the LDN Research Trust, LDN is an opioid receptor antagonist that acts as an anti-inflammatory for the central and peripheral nervous system. The drug can be used to treat a wide variety of diseases in which individuals do not naturally produce an adequate level of endorphins.
Low Dose Naltrexone (LDN) Topical Cream is compounded by HDRx according to individualized prescriber specifications, including customized concentration and base selection. A valid prescription from a licensed healthcare provider is required.
Naltrexone is classified as an opioid receptor antagonist. At lower doses, it may be incorporated into provider-directed care plans when clinically appropriate. A topical formulation may be considered when a localized delivery route is preferred as part of an individualized care strategy.
LDN is frequently discussed in clinical settings involving chronic and complex care planning. For additional educational context, explore our resources on LDN and chronic pain discussions, LDN in autoimmune-related care planning, our broader overview of LDN compounding services, and perspectives on LDN in autoimmune discussions.
For related care discussions, you may also explore mast cell stabilization considerations in MCAS and provider-directed planning for post-acute withdrawal syndrome (PAWS).
Learn more about HDRx’s approach on our dedicated LDN service page.
Compounded medications are not FDA-approved and are prepared to meet specific patient needs. Patients should consult their licensed healthcare provider to determine whether LDN is appropriate for their individual condition.
About Low Dose Naltrexone (LDN) – Endorphins are produced by the body to carry signals across synapses in the nervous system and promote cell growth throughout the body. LDN works to block opioid receptors that absorb endorphins, further increasing the endorphin level of individuals with pre-existing conditions. Read more »
